Literature DB >> 18667714

Intraperitoneal injections of low doses of C75 elicit a behaviorally specific and vagal afferent-independent inhibition of eating in rats.

Abdelhak Mansouri1, Susan Aja, Timothy H Moran, Gabriele Ronnett, Francis P Kuhajda, Myrtha Arnold, Nori Geary, Wolfgang Langhans, Monika Leonhardt.   

Abstract

Central and intraperitoneal C75, an inhibitor of fatty acid synthase and stimulator of carnitine palmitoyl-transferase-1, inhibits eating in mice and rats. Mechanisms involved in feeding inhibition after central C75 have been identified, but little is yet known about how systemic C75 might inhibit eating. One issue is whether intraperitoneal C75 reduces food intake in rats by influencing normal physiological controls of food intake or acts nonselectively, for example by eliciting illness or aversion. Another issue relates to whether intraperitoneal C75 acts centrally or, similar to some other peripheral metabolic controls of eating, activates abdominal vagal afferents to inhibit eating. To further address these questions, we investigated the effects of intraperitoneal C75 on spontaneous meal patterns and the formation of conditioned taste aversion (CTA). We also tested whether the eating inhibitory effect of intraperitoneal C75 is vagally mediated by testing rats after either total subdiaphragmatic vagotomy (TVX) or selective subdiaphragmatic vagal deafferentations (SDA). Intraperitoneal injection of 3.2 and 7.5 mg/kg of C75 significantly reduced food intake 3, 12, and 24 h after injection by reducing the number of meals without affecting meal size, whereas 15 mg/kg of C75 reduced both meal number and meal size. The two smaller doses of C75 failed to induce a CTA, but 15 mg/kg C75 did. The eating inhibitory effect of C75 was not diminished in either TVX or SDA rats. We conclude that intraperitoneal injections of low doses of C75 inhibit eating in a behaviorally specific manner and that this effect does not require abdominal vagal afferents.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18667714      PMCID: PMC2536853          DOI: 10.1152/ajpregu.90381.2008

Source DB:  PubMed          Journal:  Am J Physiol Regul Integr Comp Physiol        ISSN: 0363-6119            Impact factor:   3.619


  43 in total

1.  C75 inhibits food intake by increasing CNS glucose metabolism.

Authors:  Matthew D Wortman; Deborah J Clegg; David D'Alessio; Stephen C Woods; Randy J Seeley
Journal:  Nat Med       Date:  2003-05       Impact factor: 53.440

2.  Effect of the anorectic fatty acid synthase inhibitor C75 on neuronal activity in the hypothalamus and brainstem.

Authors:  Su Gao; M Daniel Lane
Journal:  Proc Natl Acad Sci U S A       Date:  2003-04-30       Impact factor: 11.205

3.  Comparison of central and peripheral administration of C75 on food intake, body weight, and conditioned taste aversion.

Authors:  Deborah J Clegg; Matt D Wortman; Stephen C Benoit; Charles C McOsker; Randy J Seeley
Journal:  Diabetes       Date:  2002-11       Impact factor: 9.461

4.  Reduced food intake and body weight in mice treated with fatty acid synthase inhibitors.

Authors:  T M Loftus; D E Jaworsky; G L Frehywot; C A Townsend; G V Ronnett; M D Lane; F P Kuhajda
Journal:  Science       Date:  2000-06-30       Impact factor: 47.728

5.  Role of vagal afferent innervation in feeding and brain Fos expression produced by metabolic inhibitors.

Authors:  C C Horn; M G Tordoff; M I Friedman
Journal:  Brain Res       Date:  2001-11-23       Impact factor: 3.252

6.  Inhibition of hypothalamic carnitine palmitoyltransferase-1 decreases food intake and glucose production.

Authors:  Silvana Obici; Zhaohui Feng; Arduino Arduini; Roberto Conti; Luciano Rossetti
Journal:  Nat Med       Date:  2003-05-18       Impact factor: 53.440

7.  Targeted enhancement of oleoylethanolamide production in proximal small intestine induces across-meal satiety in rats.

Authors:  Jin Fu; Janet Kim; Fariba Oveisi; Giuseppe Astarita; Daniele Piomelli
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2008-04-23       Impact factor: 3.619

Review 8.  Blood glucose dynamics and control of meal initiation: a pattern detection and recognition theory.

Authors:  L Arthur Campfield; Françoise J Smith
Journal:  Physiol Rev       Date:  2003-01       Impact factor: 37.312

9.  C75 increases peripheral energy utilization and fatty acid oxidation in diet-induced obesity.

Authors:  Jagan N Thupari; Leslie E Landree; Gabriele V Ronnett; Francis P Kuhajda
Journal:  Proc Natl Acad Sci U S A       Date:  2002-06-11       Impact factor: 11.205

10.  Pharmacological stimulation of brain carnitine palmitoyl-transferase-1 decreases food intake and body weight.

Authors:  Susan Aja; Leslie E Landree; Amy M Kleman; Susan M Medghalchi; Aravinda Vadlamudi; Jill M McFadden; Andrea Aplasca; Jayson Hyun; Erica Plummer; Khadija Daniels; Matthew Kemm; Craig A Townsend; Jagan N Thupari; Francis P Kuhajda; Timothy H Moran; Gabriele V Ronnett
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2007-12-05       Impact factor: 3.619

View more
  7 in total

1.  The lipoprivic control of feeding is governed by fat metabolism, not by leptin or adipose depletion.

Authors:  Bryan D Hudson; Alan J Emanuel; Michael F Wiater; Sue Ritter
Journal:  Endocrinology       Date:  2010-03-04       Impact factor: 4.736

2.  The central administration of C75, a fatty acid synthase inhibitor, activates sympathetic outflow and thermogenesis in interscapular brown adipose tissue.

Authors:  Priscila Cassolla; Ernane Torres Uchoa; Frederico Sander Mansur Machado; Juliana Bohnen Guimarães; Maria Antonieta Rissato Garófalo; Nilton de Almeida Brito; Lucila Leico Kagohara Elias; Cândido Celso Coimbra; Isis do Carmo Kettelhut; Luiz Carlos Carvalho Navegantes
Journal:  Pflugers Arch       Date:  2013-07-05       Impact factor: 3.657

3.  The Aversive Agent Lithium Chloride Suppresses Phasic Dopamine Release Through Central GLP-1 Receptors.

Authors:  Samantha M Fortin; Elena H Chartoff; Mitchell F Roitman
Journal:  Neuropsychopharmacology       Date:  2015-07-27       Impact factor: 7.853

4.  GIP Receptor Agonism Attenuates GLP-1 Receptor Agonist-Induced Nausea and Emesis in Preclinical Models.

Authors:  Tito Borner; Caroline E Geisler; Samantha M Fortin; Richard Cosgrove; Jorge Alsina-Fernandez; Mridula Dogra; Sarah Doebley; Marcos J Sanchez-Navarro; Rosa M Leon; Jane Gaisinsky; Arianna White; Ankur Bamezai; Misgana Y Ghidewon; Harvey J Grill; Richard C Crist; Benjamin C Reiner; Minrong Ai; Ricardo J Samms; Bart C De Jonghe; Matthew R Hayes
Journal:  Diabetes       Date:  2021-08-11       Impact factor: 9.461

5.  Nogo-A downregulation improves insulin secretion in mice.

Authors:  Claire B Bonal; Delphine E Baronnier; Caroline Pot; Mahdia Benkhoucha; Martin E Schwab; Patrice H Lalive; Pedro L Herrera
Journal:  Diabetes       Date:  2012-12-28       Impact factor: 9.461

6.  The effects of C75, an inhibitor of fatty acid synthase, on sleep and metabolism in mice.

Authors:  Jacob Pellinen; Éva Szentirmai
Journal:  PLoS One       Date:  2012-02-13       Impact factor: 3.240

7.  Possible role of intestinal fatty acid oxidation in the eating-inhibitory effect of the PPAR-α agonist Wy-14643 in high-fat diet fed rats.

Authors:  Elnaz Karimian Azari; Claudia Leitner; Thomas Jaggi; Wolfgang Langhans; Abdelhak Mansouri
Journal:  PLoS One       Date:  2013-09-17       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.